Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 800
Summary
- Conditions
- Prostatic Neoplasms
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Stratification Factors: Gleason score (<=7 versus 8-10), Regional lymph nodes involvement (N0 versus N1) Clinical T-stage (T2 and below versus T3 and above), PSA (<20ng/mL versus ? 20ng/mL) Study Site Brachytherapy (yes versus no) Pelvic Field (yes versus no) Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02446444
- Collaborators
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- National Health and Medical Research Council, Australia
- Cancer Trials Ireland
- TROG- Trans Tasman Radiation Oncology Group
- European Organisation for Research and Treatment of Cancer - EORTC
- Investigators
- Study Chair: Scott Williams ANZUP and Peter MacCallum Cancer Centre Study Chair: Paul Nguyen Dana Farber Cancer Institute and ANZUP
Get Well Soon